Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2009 - 2026)

Vertex Pharmaceuticals has reported Cash & Equivalents for 18 years, with the latest figure at $5.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 17.5% year-over-year to $5.5 billion; the trailing twelve-month figure through Mar 2026 stood at $5.5 billion (up 17.5% YoY), and the FY2025 full-year result was $5.1 billion, up 11.27% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.5 billion, up from $5.1 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $11.1 billion in Q3 2023, with the low at $4.6 billion in Q4 2024.
• Average Cash & Equivalents over 5 years is $7.4 billion, with a median of $7.6 billion recorded in 2022.
• Year-over-year, Cash & Equivalents surged 54.58% in 2022 and slumped 55.93% in 2024.
• Tracing VRTX's Cash & Equivalents over 5 years: stood at $10.5 billion in 2022, then slipped by 1.28% to $10.4 billion in 2023, then tumbled by 55.93% to $4.6 billion in 2024, then grew by 11.27% to $5.1 billion in 2025, then rose by 8.03% to $5.5 billion in 2026.
• The last three Cash & Equivalents figures came in at $5.5 billion (Q1 2026), $5.1 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.

Peer Comparison